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Introduction
Osteoporosis is a skeletal disorder characteri-
zed by an impairment of bone strength, associated
with high risk of fractures(1), due to decrease of
bone mass and deterioration of its microarchitectu-
re, which usually affects women over 50 years, both
due to menopause and aging. A rare form of osteo-
porosis is the one associated with pregnancy and
lactation. It was described for the first time over 50
years ago, when physicians identified four different
kind of pregnancy-related osteoporosis: idiopathic
osteoporosis in pregnancy, temporary osteoporosis
of the hip in pregnancy, post-gravidic vertebral
osteoporosis, and osteoporosis associated with bre-
ast-feeding(2). 
Until 1955 only few cases of vertebral fractu-
res after pregnancy were reported in literature(2).
Since then, several studies have been performed
aimed at discovering the relations between preg-
nancy and bone, and the possible therapy of osteo-
porosis in pregnancy, but they all showed contradic-
tory results(3-10).
Any epidemiological study has never been
made(11). It seems that this condition has a very low
incidence and generally it is associated with a genetic
predisposition or with other risk factors, as pre-exis-
tent deficiency and/or inadequate intake of calcium
and vitamin D, that make impossible to satisfy the
increased needs during pregnancy and lactation(10-12). 
Common clinical symptoms are back pain
during the third trimester of pregnancy, before or
after delivery, sometimes associated with vertebral
fractures, or rarely with femoral fractures(13).
Case presentation
Our patient was a nineteen years old woman,
primipara. Clinical history was negative for trauma,
falls and intensive exercise. She reported no alcohol
or cigarette consumption, and a poor intake of milk
and dairy products. During the fourth month of
Acta Medica Mediterranea, 2014, 30: 115
ABSTRACT
Osteoporosis is a skeletal disorder characterized by an impairment of bone strength, associated with high risk of fractures.
Usually it affects women over 50 years, both due to menopause and aging. A rare form of osteoporosis is the one associated with
pregnancy and lactation. Here we present the case of a young woman who developed a severe vertebral and femoral osteoporosis
after pregnancy and during lactation. This patient came to our observation after the onset of lumbar back pain associated with
severe functional limitation, so that she was not able to walk. First instrumental investigations showed a vertebral fracture and a
remarkably reduced bone mineral density (BMD), both of the rachis (total T score:-5.3 SD; Z score: -5.1 SD) and of the hip (total T
score: -3.5 SD; Z score: -3.5 SD). During the two years follow-up the patient has been treated with bisphosphonates, vitamin D ad
calcium, and has shown an improvement of clinical condition and a significant recovery of BMD. 
Key words: Secondary osteoporosis, pregnancy, bone mineral density, DXA.
Received October 08, 2013; Accepted November 10, 2013
pregnancy, she reported lumbar pain onset, with the
features of lumbosciatalgia, which a subsequent
lumbosacral magnetic resonance, MRI, proved to
be due to a L5-S1 discopathy, with notable functio-
nal limitation.
Therefore, she mentioned painkillers abuse
(non-steroidal anti-inflammatory drugs, NSAID,
and corticosteroids), with little benefit. During
puerperium symptom got worse and she was no
more able to ambulate (bedridden for almost 100
days). No complication was reported during preg-
nancy, partum and puerperium. Lactation was carri-
ed out by breastfeeding. Patient underwent anesthe-
tic block therapy by corticosteroids with partial
benefit. Meanwhile she consulted rheumatologists
and orthopaedics and underwent instrumental and
serological analyses, such as lumbosacral MRI and
electromyography (which proved to be within the
range of normality). Spinal radiography showed a
wedge vertebral fracture of D8 body (Figure 1);
pelvic radiography was negative; dual-energy X-ray
absorptiometry (DXA) showed bone mass density
(BMD) values compatible with severe osteoporosis
(lumbar spine column: total T score: -5.3 standard
deviation (SD); total Z score: -5.1 SD; hip: total T
score: -3.5 SD; Z score: -3.5 SD). Furthermore,
haematological tests were performed to exclude
causes of secondary osteoporosis: total blood cell
count, renal and hepatic function enzymes, coagula-
tion and lipid profile, iron and calcium-phosphorus
metabolism status, immunoglobulin (Ig) A, IgG,
IgM, and bone alkaline phosphatase (all within nor-
mal range); thyroid hormones dosage (normal);
parathyroid hormone (PTH), prolactin (PRL) and
human growth hormone (hGH) serum dosage (all
normal); serology for celiac disease and serum
tumoral biomarkers (all negative). A mild vitamin
D deficiency, as well as a little negative impairment
of adrenocorticotrophic hormone (ACTH) and cor-
tisol values (iatrogenic, by corticosteroid antalgic
therapy?) were detected. Orthopantomography and
odontology consultant ruled out any contraindicati-
on to bisphosphonate drug use. Therefore the pati-
ent was treated with calcium 1 g/die, Vitamin D 800
IU/die, and clodronate i.m. 100 mg/week. She was
prescribed physiokinesitherapy and to use a thora-
co-lumbo-sacral orthosis. After two years the pati-
ent is still in follow-up, showing a marked improve-
ment in overall clinical condition, absence of new
vertebral fractures, and significantly improved bone
density values (lumbar spine column: total T score:
-2.3 SD; total Z score: -2.3 SD; hip: total T score: -
3.0 SD; Z score: -3.0 SD). Finally, but not less
important, she regained ability to walk.
Discussion
Pregnancy-related osteoporosis is a rare and
idiopathic condition that occurs in young women
during their first gestation. Diagnosis is formulated
during puerperium (56% of cases) or during the
third trimester of pregnancy (41% of cases).
Pathogenesis is not yet well established; it seems to
be the result of combination of genetic and environ-
mental factors(10,11,14,15). Actually there is no evidence
that post-gravidic osteoporosis is only a pregnancy
consequence, or if it might rather depend from
underlying predisposing conditions(3). Some studies
underlined that only few patients had risk factors.
On the other hand, it is possible that genetic factors
play an important role in determining the onset of
pregnancy-related osteoporosis. A study by Dunne
et al. showed that prevalence of fragility fractures
in mothers with pregnancy-related osteoporosis
group was higher compared to the control group(16). 
During pregnancy and lactation, mother needs
to maintain her own skeletal system and to support
the growth of the fetus/baby’s one: pregnancy pro-
vides to the fetus 20-30 g of calcium, while during
lactation - which lasts nine months on average -
mother provides to the newborn 50-75 g further,
which consist approximately in 7-10% of her body
reserves of calcium. Under physiological conditi-
ons, in mother’s body occurs a modulation of mec-
hanisms that regulate calcium and phosphorus
metabolism, to ensure an adequate intake of calci-
um to the fetus(3,17). Among the hormones that regu-
late bone metabolism, parathyroid hormone (PTH)
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Figure 1: spinal radiography showing a wedge vertebral
fracture of D8 body.
and vitamin D play an important role. Data on
changes in PTH levels during pregnancy are parti-
cularly controversial; some studies show a reducti-
on of PTH levels ranging from 10% to 30% in sub-
jects during pregnancy compared to non-pregnant;
other studies however show an increase of serum
PTH(18-20). 1,25-dihydroxyvitamin D concentration
increases in serum during the second trimester and
keeps that level until the end of pregnancy(21).
During pregnancy, parathyroid hormone-related
protein (PTHrP) level raise in serum, thus determi-
ning an increase of renal 1-α-hydroxylase, a key
enzyme in vitamin D activation process. In additi-
on, some studies demonstrated a raise in calcitonin
level of serum: this hormone has an important role
in maintaining bone mass during pregnancy(16,22).
PTHrP includes a family of peptides with a consi-
derable variability; these peptides are composed by
141, 139 or 173 amino acids, and they result from a
common precursor subjected to various mRNA-
splicing. The high homology of the N-terminal
fragment allows the various PTHrP to interact with
the same PTH receptor and, consequently, to produ-
ce the same effect on the regulation of mineral
metabolism: in brief, the bone turnover accelerates
and the intestinal vitamin D-mediated absorption of
calcium increases(23,24). Both these changes are estab-
lished long before the fetus begins to accumulate
calcium for his skeleton (anticipatory storage):
some studies show that cumulative calcium balance
exceeds the fetal demands and mother reaches lac-
tation with a surplus for her skeleton(25).
Most of the authors agree that a certain loss of
bone mass occurs during lactation, but it would be
recovered after weaning, when calcium absorption
returns to the pre-pregnancy levels, while urinary
losses remain lower for several months(3,16,21,22).
Probably during pregnancy and lactation physiolo-
gical mechanisms of compensation are more effec-
tive than in other stages of life, so not all authors
agree in suggesting an higher calcium intake during
this period, because every loss is compensated by
the post-weaning adjustments. However this situati-
on might be different for both pregnant adolescents
and women under the age of 19 (as in our clinical
case); there are not wide studies showing the exis-
tence of compensation mechanisms mentioned
above, and it may be suitable to take a higher amo-
unt of calcium than that recommended in non-preg-
nant women of the same age. All aforesaid can be
strengthened by the, to date, well assessed know-
ledge that calcium supplementation in pregnancy is,
for sure, not of any damage both for the pregnant
and the unborn, reducing, at the same time, the risk
of pre-eclampsia(16,26-28). In physiological conditions
these metabolic processes of adaptation are not only
effective but also self-limiting and the eventual loss
of bone mass is subsequently recovered within a
few months, at the end of lactation. This small loss
of bone mineral density occurs in the majority of
pregnancies(3,21). 
However a loss of bone mineral density can be
seldom associated with predisposing factors and/or
pre-existing factors (such as low intake of calcium
and vitamin D, low values of bone mass before
pregnancy, twin pregnancy, or long-term breast-fee-
ding, or also other genetic factors) and thus it
results in a pronounced bone demineralization, with
a reduction of bone strength and increased risk of
fractures(12,29). 
Literature reports cases of vertebral or hip
fractures due to pregnancy-related osteoporosis.
These patients show a clinical presentation charac-
terized by acute pain poorly responsive to painkil-
lers. DXA and MRI confirm the diagnosis, after
exclusion of other secondary forms of osteoporosis
(as abnormalities of calcium metabolism, cancer
and collagen diseases) (Table 1)(30-33). Risk factors
are a matter of debate(34,35). 
In our clinical case a possible etiology is lin-
ked to the hormonal changes related with preg-
nancy, bone loss secondary to prolonged bed rest
and to the use of high doses of corticosteroids for a
period exceeding 6 months, in addition to an inade-
quate dietetic intake of calcium and vitamin D.
Intensive exercise, pathologic weight gain, history
of trauma, other predisposing medical condition
(hyperthyroidism, celiac disease), eating disorders
or family history of osteoporosis and fractures were
absent in our case.
Literature reports only few cases of preg-
nancy-related osteoporosis treated with bisphospho-
nates. Nevertheless, it seems that their use results in
significant increases in BMD(5,12,36). Few authors still
report some cases with a further decrease in bone
mineral density despite treatment with bisphospho-
nates in absence of other pregnancies(22). Our patient
was treated with calcium, vitamin D and clodrona-
te, showing significant improvements both clini-
cally, with a rapid recovery of autonomous walking,
and instrumentally, with a remarkable increase in
BMD values (lumbar spine column: total T score:
from -5.3 to -2.3 SD; total Z score: from -5.1 to -2.3
SD; hip: total T score: from -3.5 to -3.0 SD; Z
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score: from -3.5 to -3.0 SD) and without further
vertebral fractures.
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CAUSE EXAMPLES CAUSE EXAMPLES 
Genetic/congenital
• Marfan syndrome
• Ehlers-Danlos syndrome
• Menkes steely hair syndrome
• Riley-Day syndrome 
• Gaucher disease
• Glycogen storage disease
• Osteogenesis imperfecta
• Hemochromatosis
• Porphyria
• Cystic fibrosis
• Renal hypercalciuria 
• Idiopathic hypercalciuria
• Hypophosphatasia
• Homocystinuria
• Hypogonadal states
Hematologic 
and neoplastic disorders
• Thalassemia 
• Sickle cell anemia
• Hemophilia
• Hemochromatosis
• Leukemia
• Lymphoma
• Multiple myeloma
• Metastatic disease
Hypogonadal states
• Klinefelter syndrome
• Turner syndrome 
• Female athlete triad
• Anorexia nervosa/bulimia nervosa
• Panhypopituitarism
• Hyperprolactinemia
• Androgen insensitivity
• Premature menopause
Medications
• Antipsychotic drugs
• Lithium
• Selective serotonin reuptake inhibitors
• Anticonvulsants
• Aromatase inhibitors
• Chemotherapeutic/transplant drugs
• Glucocorticoids and corticotrophin
• Hormonal/endocrine therapies 
• Antiretroviral drugs
• Furosemide
• Heparin
Endocrine disorders
• Acromegaly
• Prolactinoma
• Hyperthyroidism
• Hyperparathyroidism
• Cushing syndrome
• Adrenal insufficiency
• Diabetes mellitus
• Hypogonadism
• Estrogen deficiency
• Pregnancy/lactation
Deficiency states
• Malnutrition
• Parenteral nutrition
• Malabsorption
• Gastrectomy
• Bariatric surgery
• Celiac disease
• Vitamin D deficiency
• Calcium deficiency
• Magnesium deficiency
• Protein deficiency
• Primary biliary cirrhosis
Miscellaneous
• Weightlessness 
• Alcoholism
• Immobility
• Multiple sclerosis
• Emphysema
• Chronic liver disease
• Chronic or end-stage renal disease
• Chronic metabolic acidosis
• Ochronosis
• Organ transplantation
• Sarcoidosis
• Amyloidosis
• HIV/AIDS
Inflammatory diseases
• Inflammatory bowel disease
• Ankylosing spondylitis
• Rheumatoid arthritis
• Systemic lupus erythematosus
Sources:
Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract 2013; 19:
120-8.
Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary
osteoporosis. Eur J Endocrinol 2010;  162: 1009-20.
Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin
Rheumatol 2005; 19: 1021-37.
Table 1: Etiology of secondary osteoporosis.
Trovas G, Lyritis GG, Papaioannou NA,
Tournis S. The use of bisphosphonates in
women prior to or during pregnancy and lac-
tation. Hormones 2011; 10: 280-91.
6) Ozturk C, Atamaz FC, Akkurt H, Akkoc Y.
Pregnancy-associated osteoporosis presen-
ting severe vertebral fractures. J Obstet
Gynaecol Res 2013. [Epub ahead of print]
7) Lampropoulou-Adamidou K, Trovas G,
Stathopoulos IP, Papaioannou NA. Case
report: Teriparatide treatment in a case of
severe pregnancy - and lactation- associated
osteoporosis. Hormones 2012; 11: 495-500.
8) Choe EY, Song JE, Park KH, Seok H, Lee
EJ, Lim SK, Rhee Y. Effect of teriparatide on
pregnancy and lactation-associated osteopo-
rosis with multiple vertebral fractures. J
Bone Miner Metab 2012; 30: 596-601.
9) Vujasinovic-Stupar N, Pejnovic N, Markovic
L, Zlatanovic M. Pregnancy-associated spi-
nal osteoporosis treated with bisphosphona-
tes: long-term follow-up of maternal and
infants outcome. Rheumatol Int 2012; 32:
819-23.
10) Michalakis K, Peitsidis P, Ilias I. Pregnancy-
and lactation-associated osteoporosis: a nar-
rative mini-review. Endocr Regul 2011; 45:
43-7.
11) Dunne F, Walters B, Marshall T, Heath DA:
Pregnancy associated osteoporosis. Clin
Endocrinol 1993; 39: 487-90.
12) Karlsson C, Obrant KJ, Karlsson M:
Pregnancy and lactation confer reversible
bone loss in humans. Osteoporos Int 2001;
12: 828-834.
13) He XD, Xia WB, Xing XP, Li M, Jiang Y,
Wang O, Xu LL, Xu JP. Clinical features of
pregnancy and lactation-associated osteopo-
rosis: analysis of 4 cases. Zhonghua Yi Xue
Za Zhi 2009; 89: 983-5.
14) Hirata G, Chaki O. Bone loss in lactating
women and post-pregnancy osteoporosis.
Clin Calcium 2011; 21: 1347-52.
15) Di Gregorio S, Danilowicz K, Rubin Z,
Mautalen C. Osteoporosis with vertebral
fractures associated with pregnancy and lac-
tation. Nutrition 2000; 16: 1052-5.
16) Okah FA, Tsang RC, Sierra R, Brady KK,
Specker BL. Bone turnover and mineral
metabolism in the last trimester of preg-
nancy: effect of multiple gestation. Obstet
Gynecol 1996; 88: 168-73. 
17) Kohlmeier L, Marcus R. Calcium disorders
of pregnancy. Endocrinol Metab Clin North
Am 1995; 24: 15-39.
18) Haddow JE, Neveux LM, Palomaki GE,
Lambert-Messerlian G, Canick JA, Grenache
DG, Lu J. The relationship between PTH and
25-hydroxy vitamin D early in pregnancy.
Clin Endocrinol 2011; 75: 309-14.
19) Wagner CL, Hollis BW. Beyond PTH: asses-
sing vitamin D status during early preg-
nancy. Clin Endocrinol 2011; 75: 285-6.
20) Møller UK, Streym S, Mosekilde L,
Heickendorff L, Flyvbjerg A, Frystyk J,
Jensen LT, Rejnmark L. Changes in calcitro-
pic hormones, bone markers and insulin-like
growth factor I (IGF-I) during pregnancy
and postpartum: a controlled cohort study.
Osteoporos Int 2013; 24: 1307-20.
21) Kovacs CS, Kronenberg HM. Maternal-fetal
calcium and bone metabolism during preg-
nancy, puerperium and lactation. Endocrin
Rev 1997; 18: 832-872.
22) Ardawi MS, Nasrat HA, BA'Aqueel HS.
Calcium-regulating hormones and parathy-
roid hormone-related peptide in normal
human pregnancy and postpartum: a longitu-
dinal study. Eur J Endocrinol 1997; 137: 402-
9.
23) Lanske B, Kronenberg HM. Parathyroid hor-
mone-related peptide (PTHrP) and parathy-
roid hormone (PTH)/PTHrP receptor. Crit
Rev Eukaryot Gene Expr 1998; 8: 297-320.
24) Tucci J, Beck F. Expression of parathyroid
hormone-related protein (PTHrP) and the
PTH/PTHrP receptor in the rat uterus during
early pregnancy and following artificial deci-
duoma induction. J Reprod Fertil 1998; 112:
1-10.
25) Dunne FP, Ratcliffe WA, Mansour P, Heath
DA. Parathyroid hormone related protein
(PTHrP) gene expression in fetal and extra-
embryonic tissues of early pregnancy. Hum
Reprod 1994; 9: 149-56.
26) Goldberg GR, Jarjou LM, Cole TJ, Prentice
A. Randomized, placebo-controlled, calcium
supplementation trial in pregnant Gambian
women accustomed to a low calcium intake:
effects on maternal blood pressure and infant
growth. Am J Clin Nutr 2013; 98: 972-82.
27) Buppasiri P, Lumbiganon P, Thinkhamrop J,
Ngamjarus C, Laopaiboon M. Calcium supp-
lementation (other than for preventing or
Osteoporosis in pregnancy: a case report and review of the literature 119
treating hypertension) for improving preg-
nancy and infant outcomes. Cochrane
Database Syst Rev 2011; (10): CD007079.
28) Hofmeyr GJ, Lawrie TA, Atallah AN, Duley
L. Calcium supplementation during preg-
nancy for preventing hypertensive disorders
and related problems. Cochrane Database
Syst Rev 2010; (8): CD001059.
29) Yumusakhuylu Y, Turgut ST, Icagasioglu A,
Baklacioglu HS, Atlig RS, Murat S, Suer N.
Bone mineral changes during pregnancy and
lactation. Gynecol Endocrinol 2013; 29:
763-6.
30) Lidder S, Lang KJ, Lee HJ, Masterson S,
Kankate RK. Bilateral hip fractures associa-
ted with transient osteoporosis of pregnancy.
J R Army Med Corps 2011; 157: 176-8.
31) Rajak R, Camilleri J. An unusual cause of hip
pain. BMJ Case Rep 2011; 28; 2011.
32) Emami MJ, Abdollahpour HR, Kazemi AR,
Vosoughi AR. Bilateral subcapital femoral
neck fractures secondary to transient osteo-
porosis during pregnancy: a case report. J
Orthop Surg 2012; 20: 260-2.
33) Lamarca M, Hernandez M, Campillos JM,
Lapresta M, Tobajas JJ. Subcapital fracture
of the hip in transient osteoporosis of preg-
nancy. Taiwan J Obstet Gynecol 2009; 48:
423-4.
34) Marcus R. Osteoporosis, 2nd Ed. Academic
Press, 2001; 237-58 and 669-700. 
35) Naylor KE et al the effect of pregnancy on
bone density and bone turnover. J Bone Min
Res 2000; 15: 129.
36) Mastaglia SR, Watman NP, Oliveri B.
Intravenous bisphosphonate treatment and
pregnancy: its effects on mother and infant
bone health. Osteoporos Int 2010; 21: 1959-
62.
_________
Request reprints from:
Prof. PASQUALE MANSUETO, M.D.
Dipartimento Biomedico di Medicina Interna e
Specialistica (DIBIMIS)
Università degli Studi di Palermo
Via del Vespro n°129
90127 - Palermo
(Italy)
120 Francesca Scozzari, Gian Luigi Aronica et Al
